Giuseppe Palma

Dr. Giuseppe Palma

Istituto di Nanotecnologia, Lecce, Puglia, Italy
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Physica Medica
Verified
Journal Article
Closed access
Giuseppe PalmaGiuseppe Palma
Giuseppe Palma
SMS. Monti
S. Monti
LCLaura Cella
Laura Cella

23 February 2016 in European Radiology
Verified
Journal Article
Closed access
PDF file
ETEnrico Tedeschi
Enrico Tedeschi
Giuseppe PalmaGiuseppe Palma
Giuseppe Palma
ACAntonietta Canna
Antonietta Canna
SCSirio Cocozza
Sirio Cocozza
CRCarmela Russo
Carmela Russo
Mario QuarantelliMario Quarantelli
Mario Quarantelli

1 June 2019 in Seminars in Oncology
Verified
Journal Article
Closed access
Giuseppe PalmaGiuseppe Palma
Giuseppe Palma
SMSerena Monti
Serena Monti
MCManuel Conson
Manuel Conson
RPRoberto Pacelli
Roberto Pacelli
LCLaura Cella
Laura Cella

3 August 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Serena MontiSerena Monti
Serena Monti
Giuseppe PalmaGiuseppe Palma
Giuseppe Palma
Vittoria D'AvinoVittoria D'Avino
Vittoria D'Avino
MGMarianna Alessandra Gerardi
Marianna Alessandra Gerardi
GMGiulia Marvaso
Giulia Marvaso
LCLaura Cella
Laura Cella
The risk of radiation-induced toxicity in patients treated for head and neck (HN) cancer with radiation therapy (RT) is traditionally estimated by condensing the 3D dose distribution into a monodimensional cumulative dose-volume histogram which disregards information on dose localization. We hypothesized that a voxel-based approach would identify correlations between radiation-induced morbidity and local dose release, thus providing a new insight into spatial signature of radiation sensitivity in composite regions like the HN district. This methodology was applied to a cohort of HN cancer patients treated with RT at risk of radiation-induced acute dysphagia (RIAD). We implemented an inter-patient elastic image registration framework that proved robust enough to match even the most elusive HN structures and to provide accurate dose warping. A voxel-based statistical analysis was then performed to test regional dosimetric differences between patients with and without RIAD. We identified a significantly higher dose delivered to RIAD patients in two voxel clusters in correspondence of the cricopharyngeus muscle and cervical esophagus. Our study goes beyond the well-established organ-based philosophy exploring the relationship between radiation-induced morbidity and local dose differences in the HN region. This approach is generally applicable to different HN toxicity endpoints and is not specific to RIAD.

1 October 2015 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
LCLaura Cella
Laura Cella
Vittoria D'AvinoVittoria D'Avino
Vittoria D'Avino
Giuseppe PalmaGiuseppe Palma
Giuseppe Palma
MCManuel Conson
Manuel Conson
RLRaffaele Liuzzi
Raffaele Liuzzi
RPRoberto Pacelli
Roberto Pacelli

20 December 2018 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
GPGiuseppe Pontillo
Giuseppe Pontillo
SCSirio Cocozza
Sirio Cocozza
RLRoberta Lanzillo
Roberta Lanzillo
CRCamilla Russo
Camilla Russo
MSMartina Di Stasi
Martina Di Stasi
ABArturo Brunetti
Arturo Brunetti
BACKGROUND AND PURPOSE: Deep gray matter involvement is a consistent feature in multiple sclerosis. The aim of this study was to evaluate the relationship between different deep gray matter alterations and the development of subcortical atrophy, as well as to investigate the possible different substrates of volume loss between phenotypes. MATERIALS AND METHODS: Seventy-seven patients with MS (52 with relapsing-remitting and 25 with progressive MS) and 41 healthy controls were enrolled in this cross-sectional study. MR imaging investigation included volumetric, DTI, PWI and Quantitative Susceptibility Mapping analyses. Deep gray matter structures were automatically segmented to obtain volumes and mean values for each MR imaging metric in the thalamus, caudate, putamen, and globus pallidus. Between-group differences were probed by ANCOVA analyses, while the contribution of different MR imaging metrics to deep gray matter atrophy was investigated via hierarchic multiple linear regression models. RESULTS: Patients with MS showed a multifaceted involvement of the thalamus and basal ganglia, with significant atrophy of all deep gray matter structures (P < .001). In the relapsing-remitting MS group, WM lesion burden proved to be the main contributor to volume loss for all deep gray matter structures (P ≤ .006), with a minor role of local microstructural damage, which, in turn, was the main determinant of deep gray matter atrophy in patients with progressive MS (P ≤ .01), coupled with thalamic susceptibility changes (P = .05). CONCLUSIONS: Our study confirms the diffuse involvement of deep gray matter in MS, demonstrating a different behavior between MS phenotypes, with subcortical GM atrophy mainly determined by global WM lesion burden in patients with relapsing-remitting MS, while local microstructural damage and susceptibility changes mainly accounted for the development of deep gray matter volume loss in patients with progressive MS.